Analysis Tools
immune system
|
• mutants with pre-existing anti-alpha-Gal antibodies show a median graft survival time of 14 days when ectopically grafted with C57BL/6 hearts; nae mutants with no alpha-Gal antibodies show a graft survival time of >75 days; no rapid graft rejection resembling hyperacute rejection (HAR) seen in humans is observed even with sizeable anti-alpha-Gal IgM antibody titers
(J:90851)
• mice can produce antibodies which bind alpha-Gal without need for immunization
(J:113488)
• presence of these antibodies increases B and T cell responses to poorly immunogenic antigens expressing alpha-Gal
(J:113488)
|
|
• significant alpha-BSA-specific IgG antibody levels are observed after immunization of mutants with BSA conjugated to alpha-Gal; antibody production does not require adjuvant
|
|
• anti-alpha-Gal IgG titers are low or not detectable in mutants before or after LLCa challenge; antibodies are found in only 33% of orally-immunized mutants pre-LLCa challenge
|
|
• naive mice challenged with Lewis Lung Carcinoma cells (LLCa) show production of LLCa-reactive antibodies
• in orally immunized mutants, post-challenge titers are constant or increased from pre-challenge; higher percentage of immunized mice display higher IgM titers post-challenge than nae mice
|
|
• mutants with pre-existing anti-alpha-Gal antibodies show a median graft survival time of 14 days when ectopically grafted with C57BL/6 hearts; naive mutants with no alpha-Gal antibodies show a graft survival time of >75 days; no rapid graft rejection resembling hyperacute rejection (HAR) seen in humans is observed even with sizeable anti-alpha-Gal IgM antibody titers
|
neoplasm
|
• mutant mice with higher anti-alpha-Gal IgM antibody titers at time of tumor (LLCa) challenge show delayed tumor onset (~20 days) compared to mice with low or no IgM antibodies at challenge (~12 days) suggesting tumor onset and formation times are IgM Ab-concentration dependent
|
hematopoietic system
|
• significant alpha-BSA-specific IgG antibody levels are observed after immunization of mutants with BSA conjugated to alpha-Gal; antibody production does not require adjuvant
|
|
• anti-alpha-Gal IgG titers are low or not detectable in mutants before or after LLCa challenge; antibodies are found in only 33% of orally-immunized mutants pre-LLCa challenge
|
|
• naive mice challenged with Lewis Lung Carcinoma cells (LLCa) show production of LLCa-reactive antibodies
• in orally immunized mutants, post-challenge titers are constant or increased from pre-challenge; higher percentage of immunized mice display higher IgM titers post-challenge than nae mice
|
respiratory system
|
• mutant mice with higher anti-alpha-Gal IgM antibody titers at time of tumor (LLCa) challenge show delayed tumor onset (~20 days) compared to mice with low or no IgM antibodies at challenge (~12 days) suggesting tumor onset and formation times are IgM Ab-concentration dependent
|
